Theranostic Gold Nanoparticles Modified for Durable Systemic Circulation Effectively and Safely Enhance the Radiation Therapy of Human Sarcoma Cells and Tumors  by Joh, Daniel Y. et al.
Theranostic Gold Nanoparticles
Modified for Durable Systemic
Circulation Effectively and
Safely Enhance the Radiation
Therapy of Human Sarcoma
Cells and Tumors1,2
Daniel Y. Joh*, Gary D. Kao*, Surya Murty*,
Melissa Stangl*, Lova Sun*, Ajlan Al Zaki†,
Xiangsheng Xu*, Stephen M. Hahn*,
Andrew Tsourkas† and Jay F. Dorsey*
*Department of Radiation Oncology, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, PA;
†Department of Bioengineering, School of Engineering
and Applied Sciences, University of Pennsylvania,
Philadelphia, PA
Abstract
Radiation therapy (RT) is an integral component of the treatment of many sarcomas and relies on accurate tar-
geting of tumor tissue. Despite conventional treatment planning and RT, local failure rates of 10% to 28% at
5 years have been reported for locally advanced, unresectable sarcomas, due in part to limitations in the cumu-
lative RT dose that may be safely delivered. We describe studies of the potential usefulness of gold nano-
particles modified for durable systemic circulation (through polyethylene glycosylation; hereinafter “P-GNPs”)
as adjuvants for RT of sarcomas. In studies of two human sarcoma-derived cell lines, P-GNP in conjunction with
RT caused increased unrepaired DNA damage, reflected by approximately 1.61-fold increase in γ-H2AX (histone
phosphorylated on Ser139) foci density compared with RT alone. The combined RT and P-GNP also led to signif-
icantly reduced clonogenic survival of tumor cells, compared to RT alone, with dose-enhancement ratios of 1.08
to 1.16. In mice engrafted with human sarcoma tumor cells, the P-GNP selectively accumulated in the tumor and
enabled durable imaging, potentially aiding radiosensitization as well as treatment planning. Mice pretreated
with P-GNP before targeted RT of their tumors exhibited significantly improved tumor regression and overall
survival, with long-term survival in one third of mice in this treatment group compared to none with RT only.
Interestingly, prior RT of sarcoma tumors increased subsequent extravasation and in-tumor deposition of P-GNP.
These results together suggest P-GNP may be integrated into the RT of sarcomas, potentially improving target
imaging and radiosensitization of tumor while minimizing dose to normal tissues.
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Introduction
About 15,000 new diagnoses and 5000 deaths related to sarcoma are
expected in the United States each year [1]. Multimodal treatment
consisting of surgery and radiation therapy (RT) is the mainstay of
clinical management of most sarcomas. RT has been shown to im-
prove local control rates and overall survival in patients with advanced
soft tissue sarcoma tumors of the extremity [2–4]. Furthermore, recent
analysis demonstrated that the addition of RT to surgical resection for
early-stage retroperitoneal soft tissue sarcomas significantly prolongs
survival [5]. However, such benefits have not been observed in more
advanced disease, potentially because of the inability to deliver effective
doses of RT. Current RT treatment strategies favor relatively large
margins on the radiation treatment field to address the invasive ten-
dency of many sarcomas, but the risk of excessive radiation-induced
damage to organs and surrounding tissue limits the dose of RT that
can be given to achieve local control or eradication of residual tumor
[6]. The use of adjuvant chemotherapy remains investigational because
of the risk of side effects and lack of evidence for improving overall
survival in operable disease and is thus often reserved for palliation of
metastasis [7,8]. Inadvertent damage to surrounding normal tissue is
minimized by optimizing radiation treatment planning and delivery,
including incorporating contrast-enhanced diagnostic imaging modal-
ities such as computed tomography (CT) or magnetic resonance
imaging to help delineate critical structures and appropriate treatment
margins [9]; despite these advances, however, local failure rates of
approximately 10% to 28% at 5 years are still observed [10,11].
Nanoscale agents may provide an innovative strategy for improving
the therapeutic index in treating sarcoma. In particular, gold nano-
particles (GNPs) represent a biologically safe class of materials that has
attracted considerable attention in cancer imaging and therapy. From a
diagnostic imaging perspective, gold can exhibit greater CT attenuation
at clinically relevant imaging energies than typical iodine-based agents,
rendering them especially suitable for CT-based radiation treatment
planning [12,13]. GNP may also be tunable for custom characteristics
(such as size, shape, surface chemistry, or electronic properties) and
may further undergo multiplexing with other imaging agents (such
as gadolinium or other magnetically active materials) [14,15]. Nano-
particles can accumulate passively through the enhanced permeability
and retention (EPR) effect within tumors, because of the abnormal
physiology and anatomy of tumors (i.e., leaky vasculature, large fenes-
trations in the endothelium, slow venous return, and poor lymphatic
drainage) [16]. EPR can be enhanced by chemically “decorating” nano-
particles with organic molecules [such as polyethylene glycol (PEG)],
which allow them to persist in systemic circulation for extended periods,
augmenting buildup of GNP in tumor through EPR [17]. In addition
to the prolonged systemic half-life, PEG-modified GNPs (P-GNPs) are
characterized by uniform size, relatively uncomplicated synthesis, and
stability under physiological conditions [18].
Significant radiosensitization with GNP has been reported with
orthovoltage RT [19–23] as well as megavoltage [24–26] and proton
[27,28] radiation beams. Most cell culture studies have focused
on a variety of carcinomas involving the cervix [19,23,29], prostate
[20,22,24,27], colon [21], and breast [20,24,30], among others.
Moreover, several previous studies with animal models have used
intratumoral [30,31] and intraperitoneal [32] injections of GNP or
employed RT delivery techniques that are not convenient or clinically
feasible [23,33,34]. To our knowledge, the potential for GNP for
enhancing the RT of sarcoma in both animal and cell culture models
has not yet been explored. We therefore sought to investigate the po-
tential use of GNP radiosensitizers for clinical treatment of sarcomas
by employing translational models that closely recapitulate drug
administration routes, radiation treatment planning, and the precise
and focused targeting of RT routinely used in patients.
We therefore investigated the potential of P-GNP for sarcomas,
both in cell culture and in a murine tumor model (schematic shown
in Figure 1A). Our experimental techniques included intravenous
(i.v.) administration of the P-GNP, CT imaging of mice with en-
grafted sarcoma tumors for RT treatment planning, with and with-
out P-GNP administered, and precision-targeted RT delivered using
the Small Animal Radiation Research Platform (SARRP), currently
the most advanced method of delivering image-guided stereotactic
radiotherapy to experimental animals (Figure W1). These experi-
ments together enabled us to assess the potential of P-GNP for
radiosensitizing sarcomas and improving diagnostic imaging for RT
treatment planning, using techniques similar to those employed in
clinical radiation oncology.
Materials and Methods
Synthesis and Characterization of P-GNPs
GNPs comprised of ∼12-nm colloidal core of gold were synthesized
using the Turkevich method [35]. Briefly, 60 mg of HAuCl4 (Sigma-
Aldrich, St Louis, MO) was dissolved in deionized water (200 ml),
which was heated to boiling. Aqueous sodium citrate (15 ml, 55 mM)
was then added to the boiling solution, at which point the solution
turned from clear yellow to a deep wine red. After cooling and filtering
the GNP solution through a 0.2-μm filter, methoxy-PEG-thiol [molec-
ular weight (MW) ∼ 5000; Laysan Bio Inc, Arab, AL] was added at a
4:1 weight ratio (PEG:HAuCl4) and allowed to stir overnight. The
resulting P-GNP solution was concentrated by centrifugal filtration
using 50K MWCO filters (EMD Millipore, Billerica, MA) and rinsed
seven times with phosphate-buffered saline (PBS) to remove unreacted
reagents. The gold concentration was determined using inductively
coupled plasma mass spectrometry (ICP-MS) and confirmed with
UV-Vis spectroscopy [36].
Transmission electron microscopy (TEM) images of P-GNP were
obtained by diluting P-GNP in EMD Millipore water and depositing
them on 200 mesh carbon-coated copper grids (Polysciences, Warring-
ton, PA). Samples were imaged using a JEOL 1010 transmission elec-
tron microscope operating at 80 kV, which confirmed uniform
dimensions (12.4 ± 1.3 nm; Figure 1B). For optical spectroscopy, dy-
namic light scattering (DLS), ζ potential measurements, and stock sam-
ples of P-GNPs were first diluted in PBS (pH 7.4). Optical spectra were
recorded using a Cary Bio 100 UV/visible spectrophotometer (Varian;
Agilent Technologies, Santa Clara, CA), which showed strong peaks
near ∼522 nm (Figure 1C ) due to surface plasmon resonance. DLS
measurements were performed with a Zetasizer Nano-ZS (Malvern
Instruments, Worcestershire, United Kingdom) operating in non-
invasive backscatter mode. DLS further confirmed the uniform dimen-
sions of the P-GNP, with the gold cores conjugated to the PEG chains
exhibiting hydrodynamic diameters of approximately 26 nm (Fig-
ure 1D). The low polydispersity index (a measure of nanoparticle
size inhomogeneity) that was observed reflects the high degree of size
control achieved in our synthesis (Figure 1D, inset). The ζ potential for
the P-GNP after PEG modification was measured to be near-neutral
(−0.55 mV), indicating the effective shielding of the nanoparticle
surface by the PEG groups. The physical and spectroscopic features
described here are consistent with those reported in the literature [36].
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Cell Culture
HT1080 human fibrosarcoma-derived cells were maintained in
Dulbecco’s modified Eagle’s medium, and U2OS human osteosarcoma-
derived cells were maintained in McCoy’s 5A medium (both from
Invitrogen, Carlsbad, CA). Both cell lines were obtained from American
Type Culture Collection and were tested free of mycoplasma contamina-
tion. All culture media were supplemented with 10% fetal calf serum
(Invitrogen) and 1% antibiotics (Invitrogen). Cells were maintained in
a humidified incubator that kept a 37°C and 5% CO2 environment.
Immunofluorescence for Phosphorylated Ser139
on Histone h2ax
Cancer cells grown within chamber slides were exposed to culture
medium with 1 mM P-GNP for 24 hours and then irradiated with
the SARRP (150 kVp, 15 mA) at a dose rate of 1.45 Gy/min through
a wide circular field 11-cm collimator at a distance of 35 cm from
beam to cells through a 0.15-mm copper filter. The cells were then
fixed with 10% neutral buffered formalin (Sigma-Aldrich) for 10 min-
utes at the specified time point. Cells were then rinsed with PBS, and
the nuclei were stained with Hoechst 33342 (25 μM) for 15 minutes.
The slides were permeabilized with 0.5% Triton X-100 in PBS and
then exposed to blocking buffer (PBS, 0.5% Triton X-100, 5% normal
chicken serum, 1% BSA) for 30 minutes at room temperature and
subsequently incubated overnight at 4°C with mouse monoclonal
anti–phospho-histone h2ax primary antibody (JBW301; Upstate Bio-
technology, Lake Placid, NY) at 1:1500 dilution in PBS (with 0.5%
Triton X-100 and 1% BSA). Cells were washed with PBS and then
incubated with chicken anti-mouse Alexa Fluor 594 secondary anti-
body (Molecular Probes, Eugene, OR) at 1:1000 dilution in PBS (with
0.5% Triton X-100 and 1% BSA) for 1 hour at room temperature.
After rinsing with PBS, the slides were mounted with Prolong Gold
Antifade Reagent (Invitrogen) and coverslips. Fluorescence imaging
was performed using a Deltavision Deconvolution microscope (Applied
Precision Inc, Issaquah, WA) equipped with a ×60 (1.42 NA) oil-
immersion lens and thermoelectrically cooled 12-bit monochrome
charge-coupled device (CCD) camera. Images were recorded as z-stacks
(0.5-μm steps). Following reconstructive deconvolution, the maximum
values of the pixels were used to assemble two-dimensional projec-
tions. Foci were counted in ImageJ after applying a top-hat filter and
constant value threshold based on nonirradiated controls.
Assay for Clonogenic Survival
Cells were incubated for 24 hours in culture medium with or
without 1 mM P-GNP in 60-mm dishes at predetermined densities
and then irradiated with the SARRP (150 kVp, 15 mA) at the specified
radiation doses. After replacing the culture medium, plates were kept
in a humidified incubator that maintained 37°C and 5% CO2 envi-
ronment for 10 to 14 days, when they were stained with crystal violet.
A colony by definition had N > 50 cells. The surviving fraction was
calculated as (number of colonies formed)/(number of cells plated ×
plating efficiency). Each point on the survival curve represents the
mean surviving fraction from at least three replicates. The sensitizer
Figure 1. Characterization of P-GNPs for therapy and imaging. (A) Schematic of strategy consisting of P-GNPs combined with radiation
for imaging and therapy. (B) The synthesized P-GNPs were of uniform size and shape, as shown by transmission electron micrograph of
GNP used in these investigations. (C) Optical absorption spectroscopy of GNP before and after addition of PEG chains, showing uni-
formity of light absorbance even after addition of the PEG moiety. (D) Further confirmation of uniformity of size and shape was provided
by DLS measurement of GNP before and after addition of PEG. Data were fit to Gaussian functions to determine size ± SD of the
particle distribution. Insets: Illustration of GNP with hydrodynamic diameters dH ≈ 26 nm due to the presence of PEG chains (upper)
and table of ζ potential/polydispersity index values for GNP before and after PEG modification (lower).
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enhancement ratio (SER) was calculated on the basis of the radiation
dose required to achieve a surviving fraction of 10% (DSF0.1), in which
SER = (DSF0.1 of RT only)/(DSF0.1 of P-GNP + RT).
Establishment of Human Sarcoma Tumors in Mice
Athymic nude NCr (nu/nu) mice at 6 weeks old were obtained
from National Cancer Institute (NCI). Before tumor implantation,
mice were anesthetized with 140 and 10 mg/kg ketamine and xylazine,
respectively. The mice were then injected subcutaneously with 2 ×
106 HT1080 cells suspended in Dulbecco’s modified Eagle’s medium
(50 μl) into the dorsal region near the thigh and then moved to a
heated pad. Following recovery from anesthesia, the mouse was placed
in its cage and given food and water ad libitum.
In Vivo CT Imaging and RT
The clinical RT of sarcoma commonly relies on treatment planning
that includes CT imaging of the patients in appropriate immobiliza-
tion devices and lying on “tables” similar to that used for treatment.
For animal work, this is often best simulated with the SARRP. The
SARRP is designed and created to emulate image-guided RT, with a
gantry-mounted highly collimated treatment beam that can focus on
a small treatment area, thus sparing normal tissue from inadvertent
irradiation. Furthermore, the gantry also has a mounted cone-beam
CT, enabling imaging, treatment planning, and treatment delivery
without having to move the animal to a different device or table [37].
Cone-beam CT imaging was performed using the SARRP (Gulmay
Medical, Inc, Camberley, United Kingdom). CT data were recorded at
50 kVp (0.5 mA), and 1440 projections were used to reconstruct the
cone-beam images using the algorithm provided by the manufacturer.
Mice were first imaged at baseline and then injected with 1.25 g of
P-GNP per kg through the lateral tail vein, followed by imaging at
the specified time points.
For radiotherapy treatment, anesthetized mice bearing HT1080 flank
tumors were first imaged with the SARRP as described above, and then
the CT image was used to determine the treatment isocenter for fo-
cused administration of RT (175 kVp, 15 mA) to the desired location,
which was delivered through a 17-mm diameter collimator at a distance
of 35 cm from beam to mouse through a 0.15-mm copper filter.
In Vivo Fluorescent Imaging
Ten days following mock irradiation or 20-Gy RT, mice were in-
jected with 0.15 nmol of fluorescent PEG contrast agent (IRDye
Figure 2. P-GNPs increase the density of persistent γh2ax foci of irradiated cells. (A and B) γh2ax immunofluorescence of HT1080 (A)
and U2OS (B) cells that were irradiated with 4 Gy (lower) or mock-irradiated (upper) with and without 1 mM P-GNP. Nuclear outlines
determined by Hoechst counterstaining are shown as dashed lines. (C and D) Mean γh2ax density (number of γh2ax foci per 100-μm2
nuclear area) for HT1080 (C) and U2OS (D) cells (N > 60). Error bars, 95% confidence interval.
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800CW PEG; Li-COR Biosciences, Lincoln, NE) through lateral tail
vein injection and imaged at the indicated time points using the Pearl
Impulse Imaging System.
Survival Analysis of Xenograft-Implanted Mice Treated
with RT and GNP
Mouse work was performed under a protocol approved by the
Institutional Animal Care and Use Committee (IACUC) at the Uni-
versity of Pennsylvania. Sarcoma tumors implanted into mice were
allowed to grow to a diameter of approximately 0.7 to 1 cm. Mice
were monitored daily to ensure clean cages, adequate food and water,
and good body condition. Tumor growth and mouse weight were
measured every other day. Tumor dimensions were measured with
calipers, and the volume (V ) was approximated using the equation
V ≈ [(π/6) × length × width × height]. Flank tumors were permitted
to grow no larger than V ≈ 4.2 cm3 (or a diameter of 2.0 cm) as per
IACUC standards, corresponding to roughly 6 to 10 times the original
tumor volume, at which point the animals were sacrificed. Mice were
sacrificed if they exhibited excessive weight loss (>20%), tumor metas-
tasis, lethargy, or other signs of distress consistent with IACUC stan-
dards. Survival time to this endpoint was calculated from date of
treatment. Survival data were plotted using Kaplan-Meier techniques.
Results
In Vitro Radiosensitization by P-GNPs
We first tested the effects of P-GNP on the human sarcoma cell
lines HT1080 (fibrosarcoma) and U2OS (osteosarcoma). Figure 2
shows the calculated density of DNA double-strand breaks (DSBs) in
the HT1080 and U2OS cells, respectively, which were mock-irradiated
(upper) or irradiated with 4-Gy RT (lower) either in the absence of
(left columns) or preceded by exposure to P-GNP (right columns for
each cell line). Cells treated with P-GNP consistently exhibited a higher
density of persistent phosphorylated Ser139 on histone h2ax (γh2ax)
foci, indicating greater unrepaired DNA DSBs compared to those
exposed to RT only. The density of γh2ax foci increased 1.57-fold
for HT1080 and 1.61-fold for U2OS cells compared to RT alone. Fig-
ure 2, C and D, show the calculated density of γh2ax foci (number
of foci per 100-μm2 nuclear area) for over 60 nuclei in each treatment
group for HT1080 and U2OS cells.
We subsequently tested the effects of P-GNP on the clonogenic
survival of the sarcoma cells after exposure to ionizing radiation. The
survival curves in Figure 3 show that the presence of P-GNP led to
significantly reduced clonogenic survival for both HT1080 and
U2OS cells compared to those treated with radiation alone. By fitting
each of the survival curves to a linear-quadratic model, we calculated
the SER to be 1.16 for HT1080 cells and 1.07 for U2OS cells (see
Materials and Methods section).
In Vivo Characterization of Circulating and
Tumor-Localized P-GNP
Mice i.v. injected with P-GNP were imaged with the on-board
CT of the SARRP. The imaging indicated that the P-GNP is readily
seen in the normal vasculature and is easily detectable even in smaller
vessels such as the intralobar renal veins (Figure 4, A and B). We
furthermore performed serial CT imaging to monitor the systemic per-
sistence of P-GNP. Figure 4C shows representative coronal CT images
of a mouse thorax at various time points after gold administration.
P-GNPs exhibit robust systemic half-life, as shown by the ability to
clearly delineate the chambers of the heart even at 24 hours after i.v.
administration of a single dose of P-GNP (Figure 4C ). The detect-
ability (and therefore persistence) of the P-GNP in the blood then
gradually diminished over time but still quantitatively showed CT
hyperintensity at 48 hours (IB/IM ∼ 1) compared to precontrast im-
ages (IB/IM < 1; Figure 4D; under normal contrast-free conditions,
blood is slightly less radiopaque than muscle).
In animals with engrafted sarcoma tumors, CT scanning indicated
that i.v. injected P-GNP accumulated within the tumor (Figure 4, E
and F ). The retention of the EPR-driven P-GNP within the tumor
enhanced the distinction between tumor and normal tissues, including
the depth of penetration into normal tissues by the tumor (the tumor/
normal tissue interface indicated by the blue arrows in Figure 4, E and
F ). Computer-reconstructed imaging of this mouse in three dimen-
sions further enabled us to visualize the differential distribution of
P-GNP within the tumor (Figure 4G).
To examine more closely the localization of P-GNP within tumor
tissue, we compared histologic sections of sarcoma tumors from mice
injected with saline and 1.25 g of P-GNP per kg that were stained with
both hematoxylin and eosin (H&E) and “silver enhancement” of gold,
Figure 3. Cells irradiated with GNPs exhibit decreased clonogenic survivability. (A and B) Radiation survival curves for HT1080 (A) and U2OS
(B) cell lines. Cells were irradiated after treatment with 1 mM P-GNP (red circles) or vehicle (hollow black squares). Curve fits based on
a linear-quadratic model are shown as dashed lines. Each point represents the mean surviving fraction ± SD from at least three replicates.
SER is calculated on the basis of the radiation dose required (DSF0.1) to achieve a surviving fraction of 10% with and without P-GNPs
(see Materials and Methods section).
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the latter being a signal amplification technique that can improve de-
tection of P-GNP under light microscopy through catalytic deposition
of Ag onto the nanoparticles (Figure 5A) [38]. Compared to the tumor
from the mouse injected with saline, the P-GNP–treated tumor showed
clear deposition of gold throughout tumor tissue, including EPR-driven
deposition of P-GNP especially marked in regions adjacent to tumor
vasculature, as shown in Figure 5A. Next, by quantifying the total gold
uptake in muscle, brain, and tumors using ICP-MS, we observed
that sarcoma xenografts show approximately 10 and 80 times higher
P-GNP deposition than, respectively, muscle and brain, with the
markedly reduced levels of P-GNP within brain probably due to
the protective effects of the blood-brain barrier (and consistent with
the absence of neurologic abnormalities in animal subjects following
administration of P-GNP; Figure 5B).
Figure 4. GNP-enhanced CT imaging in mice. (A and B) Coronal CT sections of the same mouse abdomen before (A) and 5 minutes after
(B) injection of P-GNP (1.25 g/kg) i.v. into the lateral tail vein. The red arrow highlights the interlobar vessels. (C and D) Sequential CT images
(transverse) of the thorax of the same mouse (C) and blood-to-muscle contrast ratio (IB/IM) at each time point (up to 48 hours after P-GNP
injection) shown in thehistograms (D). Columns inD representmean (n=3) blood-to-muscleCT intensity ratios (IB/IM) compared to precontrast
images, with error bars indicating SD. (E and F) CT imaging of a representativemouse tumor engraftedwith sarcoma cells (HT1080). The upper
images show coronal views of themouse before P-GNP injection (E) and 48 hours after injection (F) of P-GNP, whereas the lower images show
the respective transverse views. In each case, the tumors are indicated by the blue arrows. Gold accumulation is distinguished by CT hyper-
intensity at tumor site in F. (G) Three-dimensional reconstruction of the contrast-enhanced CT image in F illustrates the spatial heterogeneity
of EPR-driven P-GNP accumulation in HT1080 tumors. P-GNPs were pseudocolored in gold based on intensity thresholding.
Figure 5. Histologic and ICP-MS analyses of nanoparticle EPR in mice. (A) Representative histologic sections of sarcoma tumors excised
from mice 48 hours after i.v. injection with P-GNP (right) or saline (left) stained with H&E and silver enhancement. Blood vessels of
comparable caliber are indicated by green arrows. (B) Quantification of P-GNP accumulation in brain (n = 3), muscle (n = 3), and tumor
(n = 6) tissues measured by ICP-MS in mice sacrificed 48 hours after injection.
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P-GNP Enhances the Efficacy of Radiotherapy in Mice
Engrafted with Human Sarcoma
Having confirmed that P-GNP can accumulate in sarcomas as
described above, we next sought to assess the ability to enhance
the efficacy of RT. We therefore compared the effects of mock treat-
ment, P-GNP alone, radiation alone, or the P-GNP followed by
radiation in mice with sarcoma. The radiation was administered using
the SARRP, which enabled accurate image-guided determination
of treatment isocenter and field size and shapes to fully encompass
the tumor yet spare normal tissue. Figure 6 shows serial caliper mea-
surements of tumor volume for sarcoma-bearing mice receiving the
respective treatments. Whereas P-GNP alone did not affect tumor
growth compared to mock-treated mice, and RT alone modestly
slowed tumor growth, the combination of RT after P-GNP led to
maximal regression of tumor, with statistically significant differences
against all other groups (Figure 6A). The marked inhibition of tumor
growth provided by the combination of P-GNP followed by RT in
turn translated to significantly increased overall survival for mice in
the P-GNP plus RT group compared to all other treatment groups,
including those receiving only RT (Figure 6B). In fact, only the
mice that received P-GNP and RT showed long-term survival (with
one third of mice surviving), whereas the mice in the other treatment
groups succumbed.
Increasing P-GNP Extravasation through Tissue
Pretreatment with RT
We compared the extravasation of a fluorescently labeled PEG dye
(a bioimageable surrogate for vascular permeability) injected i.v. into
healthy mice after 20-Gy RT versus mock irradiation in the rear flank.
Figure 7A illustrates that RT 10 days before PEG dye injection leads
to persistent fluorescence over background in the irradiated zone
(indicated by the dashed circle) having the same pattern as the beam
collimator, whereas the same area in the nonirradiated mouse lacks
such features.
We then used CT contrast enhancement imaging as an indicator of
P-GNP extravasation in engrafted sarcoma tumors. The upper panel
of Figure 7B shows representative CT intensity maps of tumors from
mice receiving i.v. injection of P-GNP 10 days after mock irradiation
(left column) or 20-Gy RT (right column). The tumor receiving RT
before gold administration exhibited higher contrast enhancement
compared to the nonirradiated control, with roughly two times greater
overall brightness for the irradiated mouse compared to the nonirradi-
ated control, and this was consistent with the ICP-MSmeasurements of
P-GNP uptake for each treatment (1.8-fold increase in gold deposition;
Figure 7C).
Discussion
In this work, we investigated the imaging and radiosensitizing effects
of GNPs in cellular and animal models of human sarcoma. The radio-
sensitivities of fibrosarcoma (HT1080) and osteosarcoma (U2OS)
cells were first characterized using assays of DNA damage and clono-
genic survival. By themselves, the P-GNP had no effect on unrepaired
DNA DSBs detected by the γh2ax [39] but markedly potentiated
γh2ax phosphorylation in sarcoma cells that were subsequently irradi-
ated with a sublethal dose of ionizing radiation (Figure 2). These find-
ings are consistent with the decreased clonogenic survival of both cell
lines treated with P-GNP + RT compared to RT alone (Figure 3). Pre-
vious studies have found in vitro radiosensitization consistent with
the results shown here [23,24,30], but the observed SER has also been
shown to vary (Table W1) [21,23,40] depending on the cell line,
radiation source, field size, and also the size and shape of P-GNP
(see Table W1 for a more thorough description of SERs reported in
the literature). While RT directly damaging nuclear DNA is thought
to be most predictive for cell killing (with DSBs being the most lethal),
GNPs may also radiosensitize through alternative mechanisms such
as increasing damage to cell membrane and mitochondria, enhancing
dynamic chemical effects to further catalyze reactive oxygen species
(ROS) formation and G2/M accumulation [22,41–44]. These latter
Figure 6. GNP-enhanced RT of sarcoma improves survival in mice. (A) Tumor volumes of mice with established sarcoma tumors mock-
treated (n = 5), treated with P-GNP alone (n = 5), RT alone (n = 7), or P-GNP + RT (n = 6) were measured by calipers. Volumes were
estimated using V ≈ (π/6) (l × w × h); each point represents the mean tumor volume ± SEM. Asterisk indicates that statistical signifi-
cance (P < .05) between the RT versus GNP + RT groups was reached (α = 0.05) beginning 21 days after treatment. (B) Kaplan-
Meier survival analysis of the mice in A. Only mice treated with combined GNP + RT noted enduring survival; mice in all other treatment
groups succumbed.
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“nontargeted” mechanisms of enhancement by P-GNP can all be di-
rected at tumor tissue in vivo when combined with physiological accu-
mulation by EPR, which is potentiated by durable half-life (and further
enhanced by the addition of targeting ligands) as discussed below.
Our animal studies show that circulating P-GNPs can serve as
robust CT contrast agents that allow visualization of both vasculature
and EPR-driven deposition of gold in sarcoma tumors and by directly
exerting antitumor effects when used together with RT. Regarding the
“diagnostic” attributes of P-GNP, our investigations build on previous
studies that have suggested the value of P-GNPs as vascular imaging
agents in experimental animals [12,45]. PEG modification enables
prolonged circulation time; for example, Kommareddy and Amiji
showed that the addition of PEG ligands increased the nanoparticle
plasma half-life from 3 to 15 hours in mice [46]. Our own in vivo
imaging experiments exhibited similar durable pharmacokinetics with
the P-GNP (Figure 4, C and D), which favors greater accumula-
tion in tumors through EPR. These advantages of P-GNP together
potentially facilitate gross tumor volume contouring and RT targeting,
which in turn may help minimize inadvertent RT to normal organs
and surrounding tissues. The CT and histologic observations de-
scribed here suggest that the accumulation of P-GNP within a tumor
may be dependent on the density, location, or permeability of the
tumor neovasculature.
P-GNP may provide a means to locally potentiate RT-induced
damage to sarcoma tumors. In this work, tumor-localized accumula-
tion of P-GNP further improved the efficacy of RT by enhancing
radiation-induced damage to sarcoma tumors in vivo, as shown in
Figure 6. These observations were achieved using the SARRP, one of
the most currently advanced means of delivering tightly collimated,
accurate radiation to animals and which more closely reflects the
gantry-mounted RT given to patients. Finally, we provide evidence
that RT through its ability to permeabilize the vasculature may enhance
the passive extravasation of P-GNP, thus comprising a strategy that
could be incorporated into the fractionated treatment commonly used
in treating patients. Clinical radiotherapy protocols for sarcoma imple-
ment RT fractions of approximately 1.8 to 2 Gy (∼60-Gy cumulative
dose), and hypofractionated RT is currently being considered as a
therapeutically effective and logistically favorable alternative for elderly
patients [47]. As a proof of concept, our study used a fairly large radi-
ation dose (20 Gy) before P-GNP administration to ensure a relatively
rapid response. Translating these results to the clinical setting requires
optimization of the radiation dose and timing between RT fractions
and nanoparticle administration. While greater cumulative RT dose
increases likelihood of subsequent permeability to P-GNP extravasation,
administering nanoparticles too late in the fractionation course can
detract from the potential benefits of radiosensitization. This mutually
enhancing characteristic of radiation enhancing P-GNP uptake that,
in turn, sensitizes the sarcoma to subsequent RT fractions suggests
that P-GNP may be usefully integrated into radiation oncology in the
clinical setting.
While our cell culture and animal studies together with those
published by others have described the safety, lack of toxicity,
Figure 7. Targeted radiotherapy enhances subsequent P-GNP accumulation. (A) Serial optical imaging of fluorescently labeled PEG dye
administered i.v. in normal mice 10 days after mock irradiation (left) or irradiation with 20-Gy RT (right). The dashed orange circle outlines
the irradiated area. (B) Upper: CT intensity landscape of P-GNP contrast for sarcoma tumors mock-irradiated (left) or irradiated with
20-Gy RT (right) 10 days before gold injection. Lower: Corresponding enhancement in tumor CT intensity ratio before and after gold
injection (ET/M). (C) ICP-MS analysis of tumors excised from mice treated as in B. Data represent the means ± SE (n= 3 mice per group).
Assessing whether RT(+) group had greater P-GNP uptake than RT(−) group implemented a one-tailed t test (α = 0.05).
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pharmacokinetics, and radiosensitizing potential of nanoparticles,
these clinically important parameters are not yet well established in
humans, and thus, more extensive characterization is still required.
Reassuringly, however, gold has been used in human medicine
throughout history safely and is used today for other conditions
such as rheumatoid arthritis [48], and several formulations of GNPs
for anticancer treatment have entered clinical trials, such as CYT-
6091 [49] and AuroShell particles (clinicaltrials.gov identifier No.
NCT00848042). The results of these and future studies will help
identify the optimal integration of P-GNP into standard radiation
oncology practice.
In conclusion, we have investigated the therapeutic and diagnostic
value of P-GNP combined with RT for sarcoma. The experiments
outlined here used the SARRP to develop an integrated approach
combining both imaging and therapy that resembles clinical treatment
paradigms. Deposition of nanometer-scale agents to tumors occurred
in a tumor-specific manner through EPR. Our data suggest that
P-GNP, in conjugation with RT, enhances CT imaging and RT-
induced tumor tissue damage and provides greater mean survival times
in animal studies.
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Supplementary Materials
Mouse Irradiations with the SARRP
The SARRP (Gulmay Medical, Inc) is currently the most advanced
method to deliver RT to translational animal models. Cone-beam CT
imaging and on-board software allow detailed RT planning, and the
radiation dose can be delivered with high precision (field size as small
as 0.5 mm). For our experiments, CT data were recorded at 50 kVp
(0.5 mA), and 1440 projections were used to reconstruct the cone-
beam images using the algorithm provided by the manufacturer. Mice
were first imaged at baseline and then injected with 1.25 g of P-GNP
per kg through the lateral tail vein, followed by imaging at the spe-
cified time points. Irradiations (175 kVp, 15 mA) guided by CT
imaging were administered through a circular field 1.7-cm collimator
at a distance of 35 cm and through a 0.15-mm copper filter (for more
information, see Wong et al. [37] or visit the manufacturer’s website
at http://www.xstrahl.com/sarrp.htm; Figure W1).
Histologic Examination of Tumor Xenografts
Histologic examination of tumor xenografts is shown in Figure W2.
Weight of Treated Mice over Time
In addition to serial tumor volume measurements, we also recorded
the weight of mice over time as a surrogate marker for their ability to
thrive. We found that control mice that were mock-irradiated
lost weight much more quickly than those who received RT due to
the rapid progression of tumor growth. Furthermore, we also found
that mice receiving dual modality treatment (RT + P-GNPs) ex-
hibited greater weight gains over time after therapy compared to
RT-only group. These data together with the tumor volume measure-
ments shown in Figure 5 are suggestive of the therapeutic efficacy
of dual modality treatment and also the low toxicity of P-GNPs
(Figure W3).
Enhanced X-ray Absorption by P-GNPs
Enhanced X-ray absorption by P-GNPs is shown in Figure W4.
Distribution of Nanoparticles in Other Tissues
Distribution of nanoparticles in other tissues is shown in Figure W5.
P-GNP and Cell Proliferation
The effects of P-GNP on tumor cell proliferation are shown in
Figure W6.
Comparison of RT Enhancement from the Literature
Comparison of RT enhancement from the literature is shown in
Table W1.
Figure W1. Diagram of the SARRP and irradiation schematic.
Table W1. Comparison of GNP Radiotherapy Enhancement Selected from the Literature.
Reference Paper Citation Cell Line Radiation GNP Concentration Effect
Jain et al. Int J Radiat Oncol, 2011, 79, 531–539 MDA-MB-231 160 kVp 12 μM SER = 1.41
6 MV 12 μM SER = 1.29
15 MV 12 μM SER = 1.16
6 MeV electrons 12 μM SER = 1.04
16 MeV electrons 12 μM SER = 1.35
DU145 160 kVp 12 μM SER = 0.92
6 MV 12 μM SER = 1.13
6 MeV electrons 12 μM SER = 1.12
L132 160 kVp 12 μM SER = 1.05
6 MV 12 μM SER = 1.08
6 MeV electrons 12 μM SER = 0.97
Chattopadhyay et al. Breast Cancer Res Treat, 2013, 137, 81–91 MDA-MB-361 100 kVp 2.4 mg/ml DEF = 1.3–1.6
Chang et al. Cancer Sci, 2008, 99, 1479–1478 B16F10 6 MeV electrons 11 nM DEF ∼ 1.02
Chithrani et al. Radiat Res, 2010, 173,719–173,728 HeLa 220 kVp 1 nM DEF = 1.2–1.43
105 kVp 1 nM DEF = 1.66
6 MV 1 nM DEF = 1.17
Cs-137 (662 keV) 1 nM DEF = 1.18
Liu et al. Phys Med Biol, 2010, 55, 931–945 CT-26, EMT-7 160 kVp 0.4–1 mM DEF ∼ 1.1
CT-26, EMT-8 6 MV 0.4–1 mM DEF ∼ 1
Joh et al. PLoS One, 2013, 8, e62425 U251 150 kVp 1 mM SER ∼ 1.3
Zhang et al. Biomaterials, 2012, 33,6408–33,6419 HeLa Cs-137 (662 keV) 0.05 and 0.1 mM DEF = 1.41–1.65
Enhancement can vary on the basis of several factors, including cell line and radiation source used.
Figure W2. Histologic examination and immunofluorescent staining of HT1080 xenografts. (A) H&E staining of HT1080 tumors excised from
mice receiving the indicated treatments. (B) Cluster of differentiation 31 (CD31)/γh2ax costaining of HT1080 tumor tissue, where CD31
stains green for endothelial cells. RT and RT + GNP samples were excised from mice 24 hours after radiotherapy. In the absence of
radiotherapy, there was significantly lower expression of γh2ax foci, irrespective of GNP administration. Twenty-four hours after RT, the
immunofluorescence data show that there is more “red” signal in the RT + GNP sample compared to the RT sample, suggesting a greater
persistence of unrepaired DNA DSBs in the former. The bottom panel [RT + GNP (60 days)] shows tissue from a mouse showing full
regression of tumor 60 days after treatment, in which the tissue appears collagenous, fibrotic, and presumably absent of tumor.
Figure W4. CT contrast enhancement with P-GNPs. (A) Mass attenuation coefficients of gold compared to iodine and water. Gold exhibits
increased attenuation (μ/ρ) compared to iodine and water within the X-ray energies at diagnostic imaging photon energies. Data compiled
from the National Institute of Standards and Technology (NIST). (B) In vivo CT imaging with the SARRP (50 kVp, 0.5 mA) with and without
P-GNPs; i.v. injection (1.25 g of Au per kg) of nanoparticles showed enhanced CT contrast of mouse vasculature 5 minutes after injection,
in comparison to the control mouse.
Figure W3. Serial measurements of mouse weight. Curves represent
the average of mouse weights for each treatment group.
Figure W6. The effects of P-GNP on tumor cell proliferation. (A) Representative photograph of clonogenic survival experiment (10 days)
of nonirradiated HT1080 cells treated with vehicle (control) and with P-GNPs. While the colony density of both plates are comparable, we
observed that the control plates typically showed marginally higher colony density than those treated with nanoparticles (as shown
here). (B) A 24-hour 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay of U2OS cells treated with vehicle (control) or
1 mM P-GNPs. Similar to A, both treatment groups showed comparable viability.
Figure W5. Distributionof P-GNPs inother tissues after 48hours. The
uptake of P-GNPs in the liver, kidney, heart, lung, and brain is plotted
as percent injecteddose (%ID)per gram tissue,measured by ICP-MS.
The liver shows relatively high P-GNP uptake (comparable to that
of tumor), and this behavior is consistent with the CT hyperintensity
observed in Figure 4B.
